OncoGeneX Checkup

Ignore OncoGeneX’s (OGXI-$3.15) reported second-quarter 2014 loss of 47 cents per share. Investors, instead, should focus on existing positives and visible price catalysts coming up in the next 12-months, including:

• Management: "Based on our current expectations, we believe our capital resources will be sufficient to fund our currently planned operations into the third quarter of 2016. " Company recently completed a $22.4 million cash raise.

• The SYNERGY Trial: Results of the SYNERGY trial will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress (September) in Madrid.

• Management addressed previous unknown  raised in a recent PropThink article on ENSPIRIT trial too: "We expect to evaluate both progression-free survival, or PFS (PFS rate at 14 weeks in 170 patients), and overall survival, or OS (OS at 100 events), during the first interim futility analysis"; The first of two analyses is expected to be conducted in 2014.

• The Borealis-2 Trial (investigator-sponsored, randomized Phase 2 trial evaluating apatorsen in combination with docetaxel treatment compared to docetaxel treatment alone in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy) could be a big win, as more than 50% of patients with urothelial cancer of bladder discontinue FIRST-LINE treatment with cisplatin either due to non-responsiveness and/ or toxicity.

Continue reading at PropThink: NO ONE”S EXCITED ABOUT ONCOGENEX, WHICH MAKES IT WORTH A LOOK

Editor David J Phillips holds a financial interest in OncoGenex common stock. The 10Q Detective has a Full Disclosure Policy.